Despite encouraging results in mouse GBM models, clinical studies show major side effects of ABT263 such as thrombocytopenia and neutropenia caused by BCL-xL inhibition80, limiting the use of BCL-xL inhibitors as safe and effective anticancer agents. This evidence concerns the gene BCL2L1 and glioblastoma.